Sign up to save your podcasts
Or
Share 068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead.
SHOWNOTES:
• Read the full report "The weight is over: How GLP-1 treatments are reshaping pharma and beyond": https://t1p.de/cmjmm.
• You can also subscribe to our newsletter to stay up to date with all our latest publications: https://ludovicsubran.substack.com/.
View all episodes
By Allianz ResearchWeight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead.
SHOWNOTES:
• Read the full report "The weight is over: How GLP-1 treatments are reshaping pharma and beyond": https://t1p.de/cmjmm.
• You can also subscribe to our newsletter to stay up to date with all our latest publications: https://ludovicsubran.substack.com/.